Diagnosis and Evaluation of Bronchiectasis.
Bronchiectasis
Etiology
Prognosis
Journal
Clinics in chest medicine
ISSN: 1557-8216
Titre abrégé: Clin Chest Med
Pays: United States
ID NLM: 7907612
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
entrez:
3
3
2022
pubmed:
4
3
2022
medline:
6
5
2022
Statut:
ppublish
Résumé
Bronchiectasis is characterized by inflammation and abnormal dilatation of the airways secondary to various etiologies. A diagnosis of bronchiectasis requires that both radiological and clinical features are present. Determination of the etiology of bronchiectasis is important to allow specific treatment and should be guided by clinical features. The prognosis of bronchiectasis is highly variable, with severe cases suffering frequent exacerbations and hospitalizations, debilitating symptoms, and elevated mortality. Treatment is demanding, but adherence to treatment is associated with improved outcomes and should be assessed and reinforced. A partnership between patients and health care professionals is key to successful outcomes.
Identifiants
pubmed: 35236562
pii: S0272-5231(21)01239-9
doi: 10.1016/j.ccm.2021.11.001
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-22Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure Dr M. Shteinberg has received research grants from Novartis, Israel; Trudell pharma, Canada; GSK- Israel; travel grants from Novartis, Actelion, Boeringer Ingelheim, GSK, Rafa; speaker's fees from Boeringer Ingelheim, GSK, Astra Zeneca, Teva, Novartis, Kamada; and advisory fees from GSK, Boeringer Ingelheim, Zambon, Vertex pharmaceuticals. Dr M. Shteinberg is a member of the EMBARC group management. Dr R. Cohen has nothing to disclose.